Infosys Co-Founder and Former CEO Named Chairman

Infosys Co-Founder and Former CEO Named Chairman

Infosys edged up after co-founder and former CEO Nanaan Nilekani was named as the company’s chairman, as the India-based IT services firm tries to calm a storm after the surprise resignation of CEO Vishal Sikka last week. He said his priorities were to find a CEO, reconstitute the board and shape future strategy. Chief Operating Officer Pravin Rao has been named interim CEO and will remain in the post until […]

Read More ˃
European ADRs Trade Lower

European ADRs Trade Lower

American depository receipts of European stocks were 0.3% lower at 134.42 on the Bank of New York Mellon Europe ADR Index Thursday morning. Decliners in Continental Europe were led by Aegon-New York Shares (AEG), a Dutch life insurance, pensions and asset management company, 3.8% lower, followed by Trivago (TRVG), an online hotel search platform operator, down by 2.9% and Deutsche Bank-Global Registered Shares (DB), down by 2.3%. Novo Nordisk (NVO), […]

Read More ˃
NanoString Technologies to Collaborate With Lam Research

NanoString Technologies to Collaborate With Lam Research

NanoString Technologies said Wednesday that it has entered into a strategic collaboration with Lam Research Corporation (LRCX) to develop its proprietary Hyb & Seq next-generation sequencing platform. The objectives of the collaboration are to complete the development of the Hyb & Seq single molecule sequencing chemistry, design and engineer a clinical sequencing instrument, develop clinical assay panels, and secure the necessary regulatory approvals. In addition, the companies intend to explore […]

Read More ˃
National Retail Properties Raises 2017 Guidance

National Retail Properties Raises 2017 Guidance

National Retail Properties’ Q2 adjusted funds from operation rose to $0.65 per share from $0.60 a year earlier, exceeding Capital IQ’s poll estimate of $0.62. Revenues increased to $145.6 million from $130.9 million a year ago, also coming in ahead of the 142.8 million estimate. The company now said it expects adjusted funds from operation for 2017 to be $2.50 to $2.54 per share, up from its previous guidance of […]

Read More ˃
Galectin Therapeutics Receives Patent

Galectin Therapeutics Receives Patent

Galectin Therapeutics has received a U.S. Patent for “Method of Enhancing Specific Immunotherapies in Cancer Treatment.” Members of Galectin and Providence Cancer Center in Portland, Ore. are joint inventors on the patent, and Galectin holds the exclusive license. The patent’s principal claims cover method of use of GR-MD-02 as a means to enhance anti-tumor activity and increase survival effects of combining GR-MD-02 with multiple clinically relevant types of immune modulators, […]

Read More ˃